Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > December 15, 2022
Daily News
December 15, 2022
- Ease API Regulations to US and European Levels to Stop Generic Woes: JEMA
December 15, 2022
- Takeda’s HAE Drug Takhzyro Enjoying Positive Uptake in Japan: Exec
December 15, 2022
- Daiichi Sankyo Plots Further Growth with Enhertu Follow-Ons, Eyes Next-Gen ADCs
December 15, 2022
- Bayer Files Xarelto for Congenital Heart Disease after Fontan Procedure in Japan
December 15, 2022
- Total Sales of 25 Japan Drug Makers Up 12.9% in 1st Half, Global Players Fare Well While SMEs Falter
December 15, 2022
- Insmed’s Arikayce Braces for Price Cuts under CEA Scheme
December 15, 2022
- Ono, PrecisionLife Ink Multi-Target R&D Collab
December 15, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…